Human Papillomavirus (HPV) 16 E6 seropositivity is elevated in subjects with oral HPV16 infection |
| |
| Affiliation: | 1. Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St., Baltimore, MD 21205, United States;2. German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany;3. Maimonides Medical Center, 4802 Tenth Avenue, Brooklyn, NY 11219, United States;4. University of Pittsburgh, 3520 Fifth Avenue, Pittsburgh, PA 15213, United States;5. University of California, Los Angeles, 2-256 Factor Bldg., Los Angeles, CA 90095-1702, United States;6. Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, NY 10461, United States;7. Northwestern University, 645 N Michigan Ave., Chicago, IL 60611, United States;8. CORE Center at John H. Stroger Jr. Hospital of Cook County, 2225 W Harrison St., Chicago, IL 60612, United States;9. Ohio State University Comprehensive Cancer Center, 420 W 12th Ave., Columbus, OH 43210, United States;1. Cancer Council Queensland, PO Box 201, Spring Hill, QLD 4004, Australia;2. Menzies Health Institute Queensland, Griffith University, Gold Coast Campus, Parklands Drive, Southport, QLD 4222, Australia;3. School of Mathematical Sciences, Queensland University of Technology, ddGardens Point, Brisbane, QLD 4000, Australia;4. Menzies School of Health Research, Charles Darwin University, 147 Wharf Street, Spring Hill, QLD 4004, Australia;5. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden;6. Systems, Policy and Planning Division, Queensland Health, 147-163 Charlotte Street, Brisbane, QLD 4000, Australia;1. Department of Epidemiology, College of Public Health, University of Nebraska Medical Center, Omaha, NE, United States;2. Center for Collaboration on Research Design and Analysis, University of Nebraska Medical Center, Omaha, NE, United States;3. Department of Otolaryngology-Head and Neck Surgery, University of Nebraska Medical Center and Nebraska Methodist Hospital, Omaha, NE, United States;4. Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE, United States;5. College of Nursing, University of Nebraska Medical Center, Omaha, NE, United States;1. Biostatistics Unit, Department of Basic Sciences, Universitat Internacional de Catalunya, Sant Cugat del Vallès, Spain;2. Plan for Oncology of the Catalan Government, L’Hospitalet de Llobregat, Spain;3. Department of Clinical Sciences, School of Medicine, Universitat de Barcelona, Barcelona, Spain;4. Centre Atenció Primària Les Corts. Transverse Group for Research in Primary Care, IDIBAPS, Barcelona, Spain;5. Public Health Unit, Department of Medicine, Universitat Internacional de Catalunya, Sant Cugat del Vallès, Spain;6. EPIUnit − Instituto de Saúde Pública da Universidade do Porto (ISPUP), Porto, Portugal;7. Department of Clinical Epidemiology, Predictive Medicine and Public Health, University of Porto Medical School, Porto, Portugal;8. Tobacco Control Unit, Cancer Prevention and Control Programme, Catalan Institute of Oncology-ICO, L''Hospitalet de Llobregat, Spain;9. Cancer Control and Prevention Group, Bellvitge Biomedical Research Institute-IDIBELL, L’Hospitalet de Llobregat, Spain;1. Sam Fayad Gastro-Intestinal Viral Oncology Group, Ingham Institute for Applied Medical Research, Liverpool, Sydney, New South Wales, 2170, Australia;2. South Western Sydney Clinical School, University of New South Wales, Liverpool, Sydney, New South Wales, 2170, Australia;3. Department of Gastroenterology & Hepatology, Bankstown-Lidcombe Hospital, South Western Sydney Local Health Network, Sydney, New South Wales 2200, Australia;1. Sam Fayad Gastro-Intestinal Viral Oncology Group, Ingham Institute for Applied Medical Research, Liverpool, Sydney, New South Wales, 2170, Australia;2. South Western Sydney Clinical School, University of New South Wales, Liverpool, Sydney, New South Wales, 2170, Australia;1. Centre for Big Data Research in Health, University of New South Wales, Sydney, NSW, 2052, Australia;2. Faculty of Medicine and Health Science, Macquarie University, Sydney, NSW, 2109, Australia;3. Douglass Hanly Moir Pathology, Macquarie Park, NSW, 2113, Australia;4. Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, NSW, 2145, Australia;5. Cancer Therapy Centre, Liverpool Hospital, Liverpool, NSW, 2170, Australia;1. The Department of Digestive Surgery, Morales Meseguer Hospital, Murcia, Spain;2. Department of Surgery, Mare Nostrum International Excellence Campus, University Murcia, Spain |
| |
| Abstract: | IntroductionHuman Papillomavirus (HPV) 16 E6 serum antibodies are common in people with HPV-related oropharyngeal cancers (HPV-OPC), but not the general population. We explored HPV16 seroprevalence in people with and without oral HPV16 infection, the cause of HPV-OPC.MethodsOral rinse samples were collected semiannually and tested for 36 types of HPV DNA by PCR. HPV16 E6 serum antibodies were tested at the visit of first oral HPV detection in participants with prevalent (n = 54), or incident (n = 39) oral HPV16 DNA; or at baseline in matched participants with no oral HPV16 DNA (n = 155) using multiplex serology assay. Predictors of seropositivity were examined using logistic regression.ResultsHPV16 E6 seropositivity (7.5% vs 0.7%; p = 0.005) but not seropositivity to the other HPV16 antigens, was significantly more common in those with than without oral HPV16 infection. There were only 8 HPV16 E6 seropositive participants, but oral HPV16 DNA remained a strong predictor of E6 seropositivity after adjustment for other risk factors (aOR = 14.6 95%CI, 1.7–122.5). Seroprevalence was similar in those with prevalent (7.4%; 4/54), and incident (7.7%; 3/39) oral HPV16 infection (p = 1.00). E6 seroprevalence was associated with reduced oral HPV16 clearance, but was not statistically significant (HR = 0.65 95% CI, 0.16–2.70).Seropositive participants were primarily male (87.5%), HIV-positive (75.0%; median CD4 cell-count of 840) and had oral HPV16 DNA (87.5%). History of an HPV-related cancer (0/8) or HPV-related anogenital dysplasia (1/8) was rare, and 4 participants had recent screening showing no anogenital dysplasia.DiscussionHPV16 E6 seropositivity was higher among people with than without oral HPV16 infection, despite no known anogenital disease in these participants. |
| |
| Keywords: | Antibodies Oral HPV Seroprevalence Biomarker HPV16 E6 |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
